IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management frames Scent’s turnaround as a “long-standing initiative” to get the right balance, invest in R&D, and grow market share back—explicitly positioning R&D capability and go-to-market execution as core recovery drivers. 1
They also describe that the R&D pipeline quality has improved materially over the last ~2.5 years, going from being “not what it should have been” to now having “a very strong R&D capability,” “leading-edge new Fine Fragrances and Consumer Fragrances,” and a “great pipeline of molecules as well as delivery systems.” 2
Fine Fragrance performance is described as having managed “uncertainty and volatility in the market,” with growth coming in “slightly positive” versus expectations for mid-single-digit decline at the start of the quarter. 3
For the recovery pattern across the second half, management expects “a softer Q3” but “a stronger Q4,” producing a “second half… mid-single-digit range” trajectory for Fine Fragrance. 4
For Consumer Fragrance, management highlights rebuilding the “R&D capability” and “go-to-market approach with customers,” with the explicit intent to “drive market share gains.” 4
They also point to a good recent quarter (Q2) and then expect normalization thereafter: the business delivered “a high single-digit number” in Q2, but management expects it to normalize “to… a low single-digit number” going forward in the second half. 4
Although your question focuses on Scent’s recovery and the Fine vs Consumer split, the recovery story is also supported by Fragrance Ingredients strength—particularly in Q2—where sales grew “north of 20%” (vs a prior-year period down “10% or more”). 3
Management states the team leveraged the synthetics portfolio to capture more sales amid “macroecnomic… supply chain disruptions and higher Brent crude prices,” but expects normalization “included in our forecast for the second half… shifting back towards… higher value-added ingredients versus… traditional synthetics.” 3
They further state that Fragrance Ingredients should “normalize” on a go-forward basis and become “slightly under pressure” year-over-year, with the bigger value shift taking “more time,” primarily into next year and the year after. 4
At the segment level, Scent delivered “strong 8% growth” and Scent profitability “solid” with EBITDA growing “5% to $134 million,” driven by “volume growth and productivity gains.” 5
This matters for “recovery” because it implies the rebound is not only revenue-based but also supported by operating leverage and execution. 5
Management explicitly projects:
This expectation is consistent with their commentary that while the Middle East crisis continues, they are “factoring in a softer Q3” due to comparables (noting Q3 last year grew “20%” year-over-year). 3
Management’s framing is:
Combining the above, the Scent recovery should look like:
Management emphasizes that 2.5 years ago the R&D pipeline was behind expectations, but now IFF has a strong R&D engine with:
This indicates the R&D plan is not just incremental staffing—it is tied to the product-development “pipeline” that can sustain new launches through 2027. 2
For the businesses that R&D supports, management explicitly links progress to future competitiveness:
While this last point is about Fragrance Ingredients, it reinforces the broader R&D “timing” plan: investments are converting to competitive positioning not necessarily immediately in H2, but into 2027-era performance. 4
Management’s discussion of innovation/reinvestment is tied to sustaining the “circle where we make those investments, we get the better growth rate,” explicitly calling out the importance that “innovation matters” and that the company stays in an R&D investment band (R&D “percentage of sales… 8% to 9%”). 6
This provides context for how R&D is expected to be maintained at sufficient scale to support multi-year recovery and 2027. 6
The combination of (1) a stronger R&D capability/pipeline 2, (2) explicit intent to rebuild R&D capability and go-to-market with customers 4, and (3) ongoing emphasis on continued reinvestment and innovation 6 forms the practical plan to support 2027.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a strengthened R&D engine, including a pipeline of distinctive molecules and delivery systems, and a go-to-market revival for Consumer Fragrance. Fine Fragrance benefits from improved execution amid Middle East volatility, with an expected Q3 softness and Q4 rebound, while R&D investment positions the company for stronger competitive positioning through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF maps a resilient Scent recovery driven by Fine Fragrance stabilization, Consumer Fragrance R&D and go-to-market gains, and Fragrance Ingredients momentum, with normalization expected as Scent shifts away from synthetics. For 2H, Fine Fragrance is softer in Q3 and stronger in Q4 (mid-single-digit growth), while Consumer Fragrance should trend to low single digits. The R&D rebuild aims to fortify competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent's recovery hinges on three pillars: Fine Fragrance execution amid Middle East volatility, a Consumer Fragrance strategy built around rebuilding R&D capability and a go-to-market approach to regain market share, and a Fragrance Ingredients tailwind in Q2 that is normalizing as the portfolio shifts toward higher-value ingredients. In H2 2026, Fine Fragrance is expected to maintain mid-single-digit growth while Consumer Fragrance stabilizes at low single-digit, with R&D reinvestment driving a stronger 2027 pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a science-led recovery for Scent, driven by fragrance ingredients momentum, Fine Fragrance resilience, and a rebuilt Consumer Fragrance GTM with a stronger R&D pipeline. The company expects Q3 softness followed by a stronger Q4 in H2 2026, underpinned by an R&D-led plan for 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a path for Scent recovery anchored in a rebuilt R&D engine and an integrated go-to-market strategy, with Fine Fragrance facing a softer Q3 before a Q4 rebound and Consumer Fragrance expected to normalize to low single-digit growth in 2H 2026. The plan emphasizes higher-value ingredients and sustained R&D investment into 2027 to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a rebuilt R&D engine, with a stronger pipeline and selective management of Middle East volatility. In 2H, Fine Fragrance is expected to hover in mid-single digits (softer in Q3, stronger in Q4) while Consumer Fragrance should normalize to low single digits as go-to-market and R&D revitalization drive market share. The 2027 plan centers on sustained R&D investment and higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi